RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion - Institut de cancérologie de l'Ouest
Article Dans Une Revue Journal of Thoracic Oncology Année : 2023

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

1 IGR - Institut Gustave Roussy
2 Université Paris-Saclay
3 Humanitas Cancer Center [Milano, Italy]
4 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
5 Hôpital Louis Pradel [CHU - HCL]
6 AOUB - IRCCS Azienda Ospedaliero-Universitaria di Bologna
7 Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan]
8 Ospedale "Santa Maria della Misericordia" = University Hospital "Santa Maria della Misericordia"
9 Service de Pneumologie [CHI Créteil]
10 Vall d'Hebron University Hospital [Barcelona]
11 UNITO - Università degli studi di Torino = University of Turin
12 San Luigi Hospital [Turin, Italy]
13 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
14 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
15 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle
16 CHU Rouen
17 The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
18 University Hospital October 12
19 Institut Bergonié [Bordeaux]
20 UCBM - Università Campus Bio-Medico di Roma / University Campus Bio-Medico of Rome
21 CHU Tenon [AP-HP]
22 Hospital Italiano de Buenos Aires
23 University Hospital of Cologne [Cologne]
24 HEGP - Hôpital Européen Georges Pompidou [APHP]
25 Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse
26 Clinic Barcelona Hospital Universitari
27 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
28 Hospital General Universitario "Gregorio Marañón" [Madrid]
29 Henry Dunant Hospital [Athens, Greece]
30 UniGe - Università degli studi di Genova = University of Genoa
31 Centro Integral Oncologico Clara Campal
32 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
33 Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
34 AP-HP - Hopital Saint-Louis [AP-HP]
35 SGH - San Gerardo Hospital [Monza, Italy]
36 IPC - Institut Paoli-Calmettes
37 Imperial College London
38 Università del Piemonte Orientale - Dipartimento DISIT Italy
39 SBE - Service de biostatistique et d'épidémiologie
40 Département de médecine oncologique [Gustave Roussy]
41 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Vincent Fallet
  • Fonction : Auteur
Alessandro Russo
  • Fonction : Auteur

Résumé

Introduction: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. Methods: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. Results: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1–4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%–55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7–72.1] versus 16.3 mo [12.7–28.8], p < 0.0001). Conclusions: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients.
Fichier principal
Vignette du fichier
PIIS1556086422019943.pdf (1.55 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04176638 , version 1 (29-05-2024)

Licence

Identifiants

Citer

Mihaela Aldea, Arianna Marinello, Michaël Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04176638⟩
128 Consultations
25 Téléchargements

Altmetric

Partager

More